Fibrotech Therapeutics

Fibrotech, which specialises in renal and fibrotic diseases, was acquired by Shire, a global specialty biopharmaceutical company, for an upfront of US$75 million payment and further milestone payments of US$482.5m, making the total deal US$557.5m.

www.fibrotech.com.au

Back to List